DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note

DaVita HealthCare (DVA) recently gained 2.19% to $126.62, outpacing the S&P 500's daily loss, though it has underperformed the market over the last month. Ahead of its October 29, 2025 earnings report, analysts project Q3 EPS of $3.29 (+27.03% YoY) and revenue of $3.4 billion (+4.27% YoY), with full-year estimates forecasting EPS growth of 12.91% and revenue growth of 5.01%. The stock, currently a Zacks Rank #3 (Hold), trades at a Forward P/E of 11.34 and a PEG ratio of 0.89, both representing a notable discount to its industry averages of 21.14 and 1.88, respectively, positioning it within a top-tier Medical - Outpatient and Home Healthcare industry.

Analysis

DaVita HealthCare (DVA) demonstrated relative strength in the latest trading session, rising +2.19% to $126.62, significantly outpacing the S&P 500's daily loss of 0.16%. This recent uptick, however, follows a period of underperformance, with the stock declining 5.38% over the past month, lagging both the Medical sector's 1.54% gain and the S&P 500's 1.14% increase. Investors are keenly awaiting the company's Q3 earnings report on October 29, 2025.

Analysts project robust growth for the upcoming report, with an expected EPS of $3.29, representing a substantial 27.03% year-over-year increase, alongside revenue forecasts of $3.4 billion, up 4.27% from the prior year. For the full year, consensus estimates anticipate EPS of $10.93 (+12.91% YoY) and revenue of $13.46 billion (+5.01% YoY). Despite these positive growth expectations, the Zacks Consensus EPS estimate has remained unchanged over the last 30 days, and DVA currently holds a Zacks Rank of #3 (Hold).

From a valuation perspective, DaVita appears attractive, trading at a Forward P/E of 11.34, which is a significant discount to the industry average of 21.14. Its PEG ratio of 0.89 also stands well below the Medical - Outpatient and Home Healthcare industry's average of 1.88, suggesting potential undervaluation relative to its expected growth. The industry itself is robust, holding a Zacks Industry Rank of 36, placing it in the top 15% of all industries. This strong industry backdrop, coupled with DVA's discounted valuation, presents an interesting dynamic for the stock.

Key Decisions for Investors

• Monitor DaVita's upcoming Q3 earnings report on October 29, 2025, for confirmation of the projected 27.03% year-over-year EPS growth and 4.27% revenue increase.
• Evaluate the sustainability of DaVita's valuation discount, specifically its Forward P/E of 11.34 and PEG ratio of 0.89, relative to the higher industry averages of 21.14 and 1.88, respectively.
• Consider the implications of the unchanged Zacks Consensus EPS estimate over the last 30 days and the current Zacks Rank #3 (Hold) in conjunction with the company's strong industry positioning.